In a randomized controlled phase II study encompassing 80 patients with stage IIIB/IV NSCLC who had previously undergone first-line chemotherapy, CIMAvax-EGF demonstrated both safety and immunogenicity (274). The gene discussed is EGF; the disease is non-small cell lung carcinoma.